---
title: Unraveling MCL biology to understand resistance and identify vulnerabilities
date: '2024-03-29'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38551811/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240330180619&v=2.18.0.post9+e462414
source: Blood
description: Mantle cell lymphoma (MCL) is a rare (5-7%), aggressive B-cell non-Hodgkin's
  lymphoma with well-defined hallmarks (e.g. Cyclin D1, SOX11), and whose expansion
  is highly dependent on the tumor microenvironment (TME). Parallel drastic progresses
  in the understanding of the lymphomagenesis and improved treatments led to paradigm
  shift in this B-cell malignancy with now prolonged disease-free survival after intensive
  chemotherapy and anti-CD20 based maintenance. However, this toxic strategy is ...
disable_comments: true
---
Mantle cell lymphoma (MCL) is a rare (5-7%), aggressive B-cell non-Hodgkin's lymphoma with well-defined hallmarks (e.g. Cyclin D1, SOX11), and whose expansion is highly dependent on the tumor microenvironment (TME). Parallel drastic progresses in the understanding of the lymphomagenesis and improved treatments led to paradigm shift in this B-cell malignancy with now prolonged disease-free survival after intensive chemotherapy and anti-CD20 based maintenance. However, this toxic strategy is ...